AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01205984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
Study NCT03990610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammoplasty
Description: Undergo standard of care breast reconstructive surgery
Study NCT00342628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP
Description: DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
Study NCT01350674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: endobronchial ultrasound transbronchial needle aspiration
Study NCT03580538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistive exercise with elastic tube
Description: performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
Study NCT01819207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test by thromboelastography
Study NCT01681186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Capsule(s) (Reference)
Description: Administered orally as a capsule(s)
Study NCT01681186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Tablet (Test)
Description: Administered orally as a tablet
Study NCT01681186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Administered orally as a capsule
Study NCT01681186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s)
Description: Administered orally as a capsule(s)
Study NCT03377595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: TAP (Transversus Abdominis Plane) block
Study NCT03377595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Wound infiltration
Study NCT01000298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid placebo medication given twice per day for 7 days
Study NCT01000298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: liquid amoxicillin given twice per day for 7 days
Study NCT01000298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir
Description: liquid cefdinir given twice per day for 7 days
Study NCT02322580 — intervention group
Intervention type: DRUG
Intervention: etanercept
Study NCT01434901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
Study NCT01434901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg)
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study NCT01434901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (50 mg)
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study NCT01434901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (100 mg)
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study NCT01095081 — intervention group
Intervention type: DRUG
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
Study NCT00559104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: Unique to the Carmustine in Conditioning arm
Study NCT00559104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Used in Both Arms
Study NCT00559104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Used in Both Arms
Study NCT00559104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Description: Both arms are given autologous stem cell transplantation
Study NCT00559104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
Study NCT00559104 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation
Description: Unique to the Radiation in Conditioning Arm
Study NCT00559104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
Study NCT04463563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological
Description: Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
Study NCT02447042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of Pmsf-arm
Description: Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
Study NCT02150317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE+Sorafenib
Description: TACE followed by Sorafenib
Study NCT02150317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE alone
Study NCT03068481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration
Study NCT03068481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT03378128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (>1 cm residual disease) was performed.
Study NCT00655044 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
Study NCT01927224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (4 x 30 mg tablet)
Description: 120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
Study NCT01927224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)
Description: 120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
Study NCT01927224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502) (120 mg tablet)
Description: 120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
Study NCT05422196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Description: Addition of platelet-rich fibrin into the cleft site.
Study NCT00838890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cdc7-inhibitor (BMS-863233)
Description: Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
Study NCT03103048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With tensioned bandage
Description: All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
Study NCT00838890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cdc7-inhibitor (BMS-863233)
Description: Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
Study NCT03570645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group
Description: combination of ropivacaine and dexmedetomidine 100 ug every time
Study NCT03570645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone group
Description: combination of ropivacaine and dexamethasone 10mg every time
Study NCT03570645 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control group
Description: block with only ropivacaine
Study NCT04359654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalation Solution [Pulmozyme]
Description: Nebulised Dornase alfa 2.5mg bd for 7 days
Study NCT02420392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
Study NCT04031937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychomotor assessment
Description: the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
Study NCT03305445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (1mg/kg)
Study NCT03305445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3mg/kg)
Study NCT06165146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.
Study NCT06165146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study NCT02596919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: photography
Description: photography of meibomian glands
Study NCT01408394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ecopipam immediate release form
Description: Tablet containing 100 mg of the immediate release form of ecopipam
Study NCT03990610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer
Description: Undergo vascularized lymph node transfer
Study NCT06050343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin® Regular
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study NCT06050343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin® Regular
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study NCT06050343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinsulin® R
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study NCT06050343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rinsulin® R
Description: subcutaneous injection at a dose of 0.3 IU / kg
Study NCT01408394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg controlled release form
Description: This is the 90 mg controlled release form
Study NCT00216086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid
Study NCT01408394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180 mg controlled release form
Description: This is the 180 mg controlled release capsule
Study NCT00216086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 200 mg/m2 IV, day 1
Study NCT06522633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: The intervention involves the discontinuation of the opioid.
Description: Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
Study NCT02045147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 1a Low Cognition, Low Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation.
Study NCT02045147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 2a Low Cognition, High Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations.
Study NCT02045147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 3a Normal Cognition, Low Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals.
Study NCT02045147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grp 4a Normal Cognition, High Activation Intervention
Description: The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
Study NCT02955758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV, 200mg fixed dose, every 3 weeks
Study NCT04182724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Apatinib and Nab-paclitaxel
Description: Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
Study NCT04061525 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration
Description: Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
Study NCT03583684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Program (PRT-P)
Description: The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
Study NCT03307616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03307616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03307616 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given by mouth at bedtime: days 1-4 of Induction
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by vein: days -4 - -1 of Transplant(s)
Study NCT04597788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein supplemented very low calorie diet program
Description: Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss.
Study NCT03004287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: day 0 of Transplant(s)
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
Study NCT03004287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
Study NCT04308707 — intervention group
Intervention type: OTHER
Intervention: Breaking bad news skills
Description: Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
Study NCT00700830 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
Study NCT00955526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: 20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
Study NCT00955526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: 40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
Study NCT00955526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets once daily for 12 weeks
Study NCT03036254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBOT intervention
Description: HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2
Study NCT03036254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HBOT intervention
Description: HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2